| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1091974440 |
| P356 | DOI | 10.1007/S40744-017-0083-1 |
| P932 | PMC publication ID | 5696295 |
| P698 | PubMed publication ID | 28956301 |
| P2093 | author name string | Sumesh Kachroo | |
| Rebekah H Borse | |||
| Mohammad Ashraf Chaudhary | |||
| Noemi Muszbek | |||
| Chloe Brown | |||
| P2860 | cites work | Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab | Q24816557 |
| Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation | Q28077713 | ||
| Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis | Q33565333 | ||
| Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register | Q33742961 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index | Q34307327 | ||
| Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial | Q34568678 | ||
| Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. | Q34748136 | ||
| Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). | Q34758808 | ||
| Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway | Q35098611 | ||
| Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis | Q35553607 | ||
| Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study | Q35554918 | ||
| Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? | Q35555802 | ||
| Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis | Q35638509 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| The burden of ankylosing spondylitis. | Q36623885 | ||
| Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation | Q36891171 | ||
| Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study | Q37465416 | ||
| Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice | Q37533873 | ||
| Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal | Q38098483 | ||
| Global prevalence of ankylosing spondylitis | Q38170089 | ||
| Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. | Q42149782 | ||
| Etanercept in the longterm treatment of patients with ankylosing spondylitis | Q42619535 | ||
| Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials | Q42624096 | ||
| Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis | Q43133532 | ||
| Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis | Q44433017 | ||
| Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial | Q46919726 | ||
| The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). | Q47264127 | ||
| Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial | Q48079983 | ||
| Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial | Q48282725 | ||
| Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis | Q48400472 | ||
| Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial | Q48419903 | ||
| Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. | Q50551440 | ||
| Functional disability predicts total costs in patients with ankylosing spondylitis. | Q50690536 | ||
| Costs and quality of life of patients with ankylosing spondylitis in Canada. | Q50776850 | ||
| The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. | Q51111135 | ||
| The burden of ankylosing spondylitis in Spain. | Q51117062 | ||
| Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. | Q51295381 | ||
| The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. | Q51913051 | ||
| Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. | Q53235227 | ||
| Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report | Q57542840 | ||
| The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study | Q73023685 | ||
| Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis | Q73497781 | ||
| Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha | Q78033913 | ||
| Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) | Q81364713 | ||
| Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response | Q81515023 | ||
| A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis | Q84772075 | ||
| P433 | issue | 2 | |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| P304 | page(s) | 427-443 | |
| P577 | publication date | 2017-09-27 | |
| P1433 | published in | Rheumatology and therapy | Q27727370 |
| P1476 | title | Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective | |
| P478 | volume | 4 |
Search more.